Optimer Pharmaceuticals, Inc. (NASDAQ: OPTR) is scheduled to present at
the Cowen and Company 29th Annual Health Care Conference at
The Boston Marriott Copley Place on March 17, 2009, 1:40 p.m. Eastern
Time.
A live audio webcast of this presentation will be accessible on the
Company’s website at www.optimerpharma.com,
under the investors section. A replay of this presentation will be
available at the same location for thirty days following the meeting.
About Optimer Pharmaceuticals
Optimer Pharmaceuticals, Inc. is a biopharmaceutical company focused on
discovering, developing and commercializing innovative anti-infective
products to treat serious infections and address unmet medical needs.
Optimer has two late-stage anti-infective product candidates under
development. Fidaxomicin, formerly known as OPT-80, is the only
antibiotic therapy currently in Phase 3 worldwide clinical development
for Clostridium difficile infection. Prulifloxacin is an
antibiotic which has completed two Phase 3 clinical trials for the
treatment of travelers’ diarrhea, a form of infectious diarrhea.
Additional information can be found at http://www.optimerpharma.com.
Optimer Pharmaceuticals, Inc.
Christina Donaghy, Corporate
Communications Manager
John D. Prunty, Chief Financial Officer & VP
Finance
858-909-0736
or
Porter Novelli Life Sciences
Jason
I. Spark, Vice President
619-849-6005
